New England Journal of Medicine· 2022Q1
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- 1,569citations
- Q1SCImago
- 2022year
Short summary
A neoadjuvant PD-1 blockade with dostarlimab resulted in a clinical complete response in all 10 patients with mismatch repair-deficient, locally advanced rectal cancer, eliminating the need for standard chemoradiotherapy and surgery.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine